123 related articles for article (PubMed ID: 34590033)
1. Response to the Combination of Osimertinib, Dabrafenib, and Trametinib in Leptomeningitis From
Valet O; Swalduz A; Boussageon M; Buisson A; Avrillon V; Mastroïanni B; Pérol M
JTO Clin Res Rep; 2021 Jun; 2(6):100192. PubMed ID: 34590033
[TBL] [Abstract][Full Text] [Related]
2. Targeting
Aboubakar Nana F; Ocak S
Pharmaceutics; 2021 Sep; 13(9):. PubMed ID: 34575554
[TBL] [Abstract][Full Text] [Related]
3. Durable Clinical Response of Advanced Lung Adenocarcinoma Harboring
Ding H; Zhuang Z; Xie J; Huang H; Tao Z; Liu Z
Onco Targets Ther; 2020; 13():7933-7939. PubMed ID: 32848419
[TBL] [Abstract][Full Text] [Related]
4. Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient.
Ribeiro MFSA; Knebel FH; Bettoni F; Saddi R; Sacardo KP; Canedo FSNA; Alessi JVM; Shimada AK; Marin JFG; Camargo AA; Katz A
NPJ Precis Oncol; 2021 Feb; 5(1):5. PubMed ID: 33580193
[TBL] [Abstract][Full Text] [Related]
5. Pretreated
Orciuolo C; Cappuzzo F; Landi L; Resuli B; Carpano S; Vidiri A; Buglioni S; Mandoj C; Ciliberto G; Minuti G
JTO Clin Res Rep; 2023 Aug; 4(8):100545. PubMed ID: 37533438
[TBL] [Abstract][Full Text] [Related]
6. EGFR/BRAF/MEK co-inhibition for EGFR-mutated lung adenocarcinoma patients with an acquired BRAF
Zeng R; Luo L; Sun X; Bao Z; Du W; Dai R; Tang W; Gao B; Xiang Y
Cancer Drug Resist; 2021; 4(4):1019-1027. PubMed ID: 35582379
[TBL] [Abstract][Full Text] [Related]
7. MAP2K1 K57N Conferred an Acquired Resistance to Furmonertinib, Dabrafenib and Trametinib Combined Therapy in Advanced Lung Adenocarcinoma with EGFR Mutation and BRAF V600E.
Tan X; Wu Z; Chen M
Onco Targets Ther; 2024; 17():307-312. PubMed ID: 38617091
[TBL] [Abstract][Full Text] [Related]
8. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring
Odogwu L; Mathieu L; Blumenthal G; Larkins E; Goldberg KB; Griffin N; Bijwaard K; Lee EY; Philip R; Jiang X; Rodriguez L; McKee AE; Keegan P; Pazdur R
Oncologist; 2018 Jun; 23(6):740-745. PubMed ID: 29438093
[TBL] [Abstract][Full Text] [Related]
9. Dabrafenib plus trametinib in patients with previously untreated BRAF
Planchard D; Smit EF; Groen HJM; Mazieres J; Besse B; Helland Å; Giannone V; D'Amelio AM; Zhang P; Mookerjee B; Johnson BE
Lancet Oncol; 2017 Oct; 18(10):1307-1316. PubMed ID: 28919011
[TBL] [Abstract][Full Text] [Related]
10. Adverse Event Management in Patients with
Chalmers A; Cannon L; Akerley W
Oncologist; 2019 Jul; 24(7):963-972. PubMed ID: 30598499
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Dabrafenib Plus Trametinib Combination in Patients with
Auliac JB; Bayle S; Do P; Le Garff G; Roa M; Falchero L; Huchot E; Quéré G; Jeannin G; Métivier AC; Hobeika J; Guisier F; Chouaid C
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33276639
[TBL] [Abstract][Full Text] [Related]
12. An advanced pulmonary sarcomatoid carcinoma patient harboring a BRAF
Fang R; Gong J; Liao Z
Front Oncol; 2023; 13():1220745. PubMed ID: 37546400
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF
Facchinetti F; Lacroix L; Mezquita L; Scoazec JY; Loriot Y; Tselikas L; Gazzah A; Rouleau E; Adam J; Michiels S; Massard C; André F; Olaussen KA; Vassal G; Howarth K; Besse B; Soria JC; Friboulet L; Planchard D
Eur J Cancer; 2020 Jun; 132():211-223. PubMed ID: 32388065
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
[TBL] [Abstract][Full Text] [Related]
15. Dabrafenib plus trametinib in patients with BRAF
Subbiah V; Lassen U; Élez E; Italiano A; Curigliano G; Javle M; de Braud F; Prager GW; Greil R; Stein A; Fasolo A; Schellens JHM; Wen PY; Viele K; Boran AD; Gasal E; Burgess P; Ilankumaran P; Wainberg ZA
Lancet Oncol; 2020 Sep; 21(9):1234-1243. PubMed ID: 32818466
[TBL] [Abstract][Full Text] [Related]
16. Durable Response of Dabrafenib, Trametinib, and Capmatinib in an NSCLC Patient With Co-Existing BRAF-KIAA1549 Fusion and MET Amplification: A Case Report.
Chou YT; Lin CC; Lee CT; Pavlick DC; Su PL
Front Oncol; 2022; 12():838798. PubMed ID: 35372088
[No Abstract] [Full Text] [Related]
17. Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report.
Adachi Y; Yanagimura N; Suzuki C; Ootani S; Tanimoto A; Nishiyama A; Yamashita K; Ohtsubo K; Takeuchi S; Yano S
BMC Cancer; 2020 Feb; 20(1):156. PubMed ID: 32093631
[TBL] [Abstract][Full Text] [Related]
18. Tumor response to EGFR/BRAF/MEK co-inhibition in a patient with EGFR mutated lung adenocarcinoma developing a BRAF
Mauclet C; Collard P; Ghaye B; Hoton D; Nana FA
Lung Cancer; 2021 Sep; 159():42-44. PubMed ID: 34304052
[TBL] [Abstract][Full Text] [Related]
19. Cyclin-dependent kinase 4 upregulation mediates acquired resistance of dabrafenib plus trametinib in
Hirai N; Hatanaka Y; Hatanaka KC; Uno Y; Chiba SI; Umekage Y; Minami Y; Okumura S; Ohsaki Y; Sasaki T
Transl Lung Cancer Res; 2021 Sep; 10(9):3737-3744. PubMed ID: 34733624
[TBL] [Abstract][Full Text] [Related]
20. Severe Epistaxis Secondary to Dabrafenib and Trametinib Toxicity in Non-small Cell Lung Carcinoma With Small Bowel Metastasis.
Gullapalli K; Mosalem O; Varghese MT; Watat K; Hrinczenko B
Cureus; 2021 Jul; 13(7):e16431. PubMed ID: 34466299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
